SecBot SecBot

MDWD

MediWound Ltd.
Nasdaq· Medicinal Chemicals & Botanical Products· Inc. L3· CIK 0001593984 Biotech & Drug Discovery
$13.55 +0.65 (+5.04%)
Nov 16 4:00 PM ET · prev $12.90
Market cap
$185.6M
Micro cap
Median target
$30.00
+121% · range $25.00–36.00
1 year
−26.3%
from $18.38 · Nov 17
30 days
+6.7%
from $12.70
52-week range
$11.85–19.37
−30% from high · low Oct 16
Avg volume 20D
168.6K
shares / day
Short interest
1.79M
≈12.4% of shares · +2.3%
Days to cover
14.7
at average volume
Insider net
+$60.6K
3 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 5 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 5/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    3 insiders bought $142.7K at an average $13.97. 2 insiders sold $82.1K.

  • InstitutionsMIXED

    Q3 2026: 6 added (0 new), 7 trimmed or exited.

  • Short sellersSTEADY

    Short interest +2.3% to 1.79M shares. 14.7 days to cover, ≈12.4% of shares.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGTRIM110,894$1.5M
Russell Investments Group, Ltd.DOUBLED57,494$791.7K
Nuveen, LLCADD17,159$236.3K
FMR LLCADD9,709$133.7K
BARCLAYS PLCDOUBLED4,069$56.0K
BNP PARIBAS FINANCIAL MARKETSADD2,441$33.6K
Arax Advisory PartnersTRIM1,151$15.8K
CITIGROUP INCNEAR_EXIT1,031$14.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
12-month targets · 6 analysts

Price is below the lowest target. Median implies +121%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 14, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
May 28, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
May 28, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$142.7K
bought · 3 insiders
$82.1K
sold · 2 insiders
−3.0%
vs their $13.97 cost
DateInsiderTypeValue
Nov 11, 2026
Gonen Ofer
Chief Executive Officer
Nov 11, 2026
EXERCISE$110.1K
Nov 11, 2026
Gonen Ofer
Chief Executive Officer
Nov 11, 2026
EXERCISE8,168 sh
Nov 10, 2026
Fox David Morton
Director
Nov 10, 2026
EXERCISE$88.0K
Nov 10, 2026
Fox David Morton
Director
Nov 10, 2026
EXERCISE6,534 sh
Nov 10, 2026
SHAMIR NACHUM
Director
Nov 10, 2026
EXERCISE$220.1K
Nov 10, 2026
SHAMIR NACHUM
Director
Nov 10, 2026
EXERCISE16,336 sh
Sep 1, 2026
Rubinstein Samuel
Director
Sep 1, 2026
BUY$6.6K
Sep 1, 2026
Rubinstein Samuel
Director
Sep 1, 2026
SELL$6.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.60-$0.70–-$0.53+3.0%$6.7M
Current FY-$2.02-$2.21–-$1.85+9.5%$18.4M
Next FY-$2.24-$2.84–-$1.77+2.0%$28.3M

Short side

FINRA· Oct 30, 2026
1,790,576
shares short
+2.3%
vs prior settlement
14.7
days to cover
≈12.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Rosalind Advisors and related entities filed an amended Schedule 13G disclosing beneficial ownership of 1,312,319…
SC 13G/A · Impact 3/10
Nov 12, 2026 SEC
MediWound reported Q3 2026 revenue of $3.6M, down 33% YoY from $5.4M, and a net loss of $0.46 per share vs $0.24 a…
6-K · Impact 6/10
Nov 12, 2026 SEC
MediWound reported Q3 2026 revenue of $3.6M, down 33% YoY from $5.4M, and a net loss of $0.46 per share, wider than…
PRESS-RELEASE · Impact 6/10
Nov 12, 2026 Earnings
MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by
Nov 11, 2026 Insider
Gonen Ofer acquired via exercise 8,168 shares
Chief Executive Officer @ $13.48 ($110.1K)
Nov 11, 2026 Insider
Gonen Ofer acquired via exercise 8,168 shares
Chief Executive Officer
Nov 10, 2026 Insider
Fox David Morton acquired via exercise 6,534 shares
Director @ $13.48 ($88.0K)
Sep 30, 2026 Inst.
UBS Group AG · TRIM
110,894 shares ($1.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

10 filings · 3 press releases · 1 bullish · 6 bearish · 3 neutral
All MDWD filing & press-release reports (13)